Inactive Ingredient Search for Approved Drug Products
You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with D
| Quarter | Inactive Ingredient | Route of Administration | Dosage Form | Maximum Potency per unit dose | Maximum Daily Exposure | Status | |
|---|---|---|---|---|---|---|---|
| Q1 2024 | DIETHYLENE GLYCOL MONO AND DIPALMITOSTEARATE | VAGINAL | CREAM | 16500mg | Correction | ||
| Q2 2024 | DIETHYLENE GLYCOL MONO- AND DIPALMITOSTEARATE | VAGINAL | CREAM | 16500mg | Correction | ||
| Q1 2024 | DURO-TAK 87-2070 | TRANSDERMAL | FILM, EXTENDED RELEASE | NA | Correction | ||
| Q1 2024 | DURO-TAK 87-2070 | TRANSDERMAL | SYSTEM | NA | Correction | ||
| Q1 2024 | DURO-TAK 87-2194 | TRANSDERMAL | FILM, EXTENDED RELEASE | 208.28 mg | Correction | ||
| Q1 2024 | DURO-TAK 87-2287 | TRANSDERMAL | FILM | 537.70 mg | Correction | ||
| Q1 2024 | DURO-TAK 87-2287 | TRANSDERMAL | FILM, EXTENDED RELEASE | 121.10 mg | Correction | ||
| Q1 2024 | DURO-TAK 87-2287 | TRANSDERMAL | SYSTEM | 305.89 mg | Correction | ||
| Q2 2024 | D&C RED NO. 21--ALUMINUM LAKE | ORAL | CAPSULE | NA | Deletion | ||
| Q2 2024 | D&C RED NO. 21--ALUMINUM LAKE | ORAL | TABLET, CHEWABLE | NA | Deletion | ||
| Q2 2024 | DEXTROSE | INTRAVENOUS | POWDER, FOR SOLUTION | 5.02 %w/v | Deletion | ||
| Q1 2024 | D&C RED NO. 30 ALUMINUM LAKE | ORAL | CAPSULE, DELAYED RELEASE | 0.30 mg | MDE Replacement | ||
| Q2 2024 | D&C RED NO. 30 ALUMINUM LAKE | ORAL | CAPSULE, DELAYED RELEASE | 5mg | MDE Replacement | ||
| Q1 2024 | D&C RED NO. 30 ALUMINUM LAKE | ORAL | TABLET, EXTENDED RELEASE | 0.10 mg | MDE Replacement | ||
| Q2 2024 | D&C RED NO. 30 ALUMINUM LAKE | ORAL | TABLET, EXTENDED RELEASE | 1mg | MDE Replacement |
FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections: IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly
Data Through: March 15, 2024
Database Last Updated: April 29, 2024